Bank Of America Corp Cyteir Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.84 - $3.13 $25,077 - $27,637	8,830 Added 10.97%	89,304 $271,000
Q2 2023 Aug 14, 2023	BUY	$1.74 - $2.6 $22,506 - $33,631	12,935 Added 19.15%	80,474 $209,000
Q1 2023 May 12, 2023	BUY	$1.47 - $1.84 $62,801 - $78,608	42,722 Added 172.15%	67,539 $122,000
Q4 2022 Feb 10, 2023	BUY	$1.18 - $1.76 $4,495 - $6,705	3,810 Added 18.14%	24,817 $40,000
Q3 2022 Nov 14, 2022	SELL	$1.99 - $4.05 $10,668 - $21,712	-5,361 Reduced 20.33%	21,007 $40,000
Q2 2022 Aug 12, 2022	BUY	$1.62 - $4.4 $3,463 - $9,407	2,138 Added 8.82%	26,368 $78,000
Q1 2022 May 16, 2022	BUY	$3.39 - $10.51 $30,123 - $93,391	8,886 Added 57.91%	24,230 $92,000
Q4 2021 Feb 08, 2022	BUY	$9.83 - $19.21 $29,647 - $57,937	3,016 Added 24.46%	15,344 $175,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $179,473 - $269,271	12,318 Added 123180.0%	12,328 $216,000
Q2 2021 Sep 13, 2021	BUY	$16.8 - $21.4 $168 - $214	10 New	10 $0

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.